Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher H Domen

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Applied Neuropsychology. Adult|September 6, 2018
Comparing two models of performance validity assessment in patients with Parkinson's disease who are candidates for deep brain stimulation surgeryThomas R Wodushek, Christopher H Domen
Epilepsy & Behavior Reports|September 10, 2019
The impact of cannabis use on intracarotid amobarbital testingChristopher H Domen, Archana Shrestha, Kevin Chapman, et al.
The Clinical Neuropsychologist|July 4, 2020
The APPCN multisite didactic initiative: Development, benefits, and challengesChristopher H Domen, Robert L Collins, Jeremy J Davis
Multiple Sclerosis and Related Disorders|December 4, 2018
Exploring cannabis use by patients with multiple sclerosis in a state where cannabis is legalLaura Weinkle, Christopher H Domen, Ian Shelton, et al.
Movement Disorders Clinical Practice|April 8, 2022
Higher Risk, Higher Reward? Self-Reported Effects of Real-World Cannabis Use in Parkinson's DiseaseSamantha K Holden, Christopher H Domen, Stefan Sillau, et al.
Archives of Clinical Neuropsychology : the Official Journal of the National Academy of Neuropsychologists|March 19, 2020
Are Established Embedded Performance Validity Test Cut-Offs Generalizable to Patients With Multiple Sclerosis?Christopher H Domen, Michael R Greher, Patrick W Hosokawa, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 22, 2023
Cognitive Safety Data from a Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase IIb Study of the Effects of a Cannabidiol and Δ9-Tetrahydrocannabinol Drug on Parkinson's Disease-Related Motor SymptomsChristopher H Domen, Stefan Sillau, Ying Liu, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 15, 2024
Short-Term Cannabidiol with Δ-9-Tetrahydrocannabinol in Parkinson's Disease: A Randomized TrialYing Liu, Jacquelyn Bainbridge, Stefan Sillau, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Applied Neuropsychology. Adult|September 6, 2018
Comparing two models of performance validity assessment in patients with Parkinson's disease who are candidates for deep brain stimulation surgeryThomas R Wodushek, Christopher H Domen
Epilepsy & Behavior Reports|September 10, 2019
The impact of cannabis use on intracarotid amobarbital testingChristopher H Domen, Archana Shrestha, Kevin Chapman, et al.
The Clinical Neuropsychologist|July 4, 2020
The APPCN multisite didactic initiative: Development, benefits, and challengesChristopher H Domen, Robert L Collins, Jeremy J Davis
Multiple Sclerosis and Related Disorders|December 4, 2018
Exploring cannabis use by patients with multiple sclerosis in a state where cannabis is legalLaura Weinkle, Christopher H Domen, Ian Shelton, et al.
Movement Disorders Clinical Practice|April 8, 2022
Higher Risk, Higher Reward? Self-Reported Effects of Real-World Cannabis Use in Parkinson's DiseaseSamantha K Holden, Christopher H Domen, Stefan Sillau, et al.
Archives of Clinical Neuropsychology : the Official Journal of the National Academy of Neuropsychologists|March 19, 2020
Are Established Embedded Performance Validity Test Cut-Offs Generalizable to Patients With Multiple Sclerosis?Christopher H Domen, Michael R Greher, Patrick W Hosokawa, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 22, 2023
Cognitive Safety Data from a Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase IIb Study of the Effects of a Cannabidiol and Δ9-Tetrahydrocannabinol Drug on Parkinson's Disease-Related Motor SymptomsChristopher H Domen, Stefan Sillau, Ying Liu, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 15, 2024
Short-Term Cannabidiol with Δ-9-Tetrahydrocannabinol in Parkinson's Disease: A Randomized TrialYing Liu, Jacquelyn Bainbridge, Stefan Sillau, et al.
Pageof 1